Navigation Links
DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
Date:7/15/2013

CAMBRIDGE, Mass., July 15, 2013 /PRNewswire/ --DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), has initiated a phase 1b/2a study of its lead drug candidate, HT-100 (delayed-release halofuginone). The phase 1b study (with a six-month 2a extension) in patients will determine the safety and tolerability of different, increasing doses of HT-100, and explore trends in a range of efficacy endpoints.    

HT-100 is an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle fiber regeneration in boys with DMD. The phase 1b/2a clinical program will enroll 30 boys and young men with DMD, both ambulatory and non-ambulatory. Participating centers include University of California, Davis Medical Center (Sacramento, Calif.), Kennedy Krieger Institute, Johns Hopkins School of Medicine (Baltimore, MD), Washington University School of Medicine (St. Louis, MO), Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio) and Nationwide Children's Hospital (Columbus, Ohio). DART expects to complete the study in mid 2014.

"Treating DMD requires a cocktail of therapies that will change over time," said Gene Williams, CEO of DART Therapeutics. "We believe HT-100 could be a valuable part of this cocktail—even a mini-cocktail on its own—because it demonstrates potential to address many different aspects of the disease in parallel, which could make it an exceptionally important therapy for all boys living with DMD."

DART's study will include boys aged six through 20, an atypical age range that allows investigators to evaluate HT-100's safety in a broad population as well as study its effect in different d
'/>"/>

SOURCE DART Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
2. Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
3. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
4. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
5. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
6. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
7. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Hologic, Inc. (NASDAQ: ... of the 2.00% Convertible Exchange Senior Notes due 2037 ... Wilmington Trust Company, the trustee, paying agent and conversion ... convert the notes.  This conversion right is subject to ... dated as of December 10, 2007, as supplemented by ...
(Date:4/1/2015)... and ASPEN, Colo. , ... partnership with the Chris Klug Foundation (CKF), is pleased to ... now being accepted for the award, which will recognize ... of life, whether it is a career accomplishment, participation ... fulfilling life with family and loved ones. ...
(Date:4/1/2015)... , Mar. 31, 2015 Research and Markets ... addition of the "Metabolic Testing Market by ... by Application (Critical Care, Lifestyle Diseases), by Technology ... Sports, Hospital) - Global Forecast to 2019 " ... global metabolic testing market is expected to reach ...
Breaking Medicine Technology:Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3Global Metabolic Testing (CPET, Body Composition Analysis, ECG, Portable System) Market 2015-2019 - REE, Body Composition Analysis for Gyms, Sports & Hospital 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 Baby Bellies ... providing the latest information on the top products and ... set the Guinness World Records title for "Mommy Moments” ... of the 1st annual Baby Bellies & Beyond Expo ... and the Guinness World Record will commence at 11:00am ...
(Date:4/1/2015)... New York, New York (PRWEB) April 01, 2015 ... litigation housing hundreds of Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ... According to the calendar for the Philadelphia Court of ... in Court Room 206, City Hall. Court records indicate ... liability claims filed on behalf of Risperdal users who ...
(Date:4/1/2015)... April 01, 2015 BioPlus Specialty ... specialty pharmacies, has released a new app to keep ... for treating chronic hepatitis C virus (HCV) infection. This ... on information from the American Association for the Study ... , Numerous new direct-acting oral medications to treat HCV ...
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross and ... (Blue Cross) today announced audited financial results for 2014. ... of $61.5 million, reflecting positive investment portfolio performance that ... operating loss of $8.2 million on full-year revenues of ... of one percent (0.1%). , Blue Cross reported ...
(Date:4/1/2015)... 2015 Dr. Daniel C. Stewart ... April to discuss the benefits of the LANAP® treatment ... from periodontal disease. People who live in Howard County, ... disease can now visit Dr. Stewart, a Maryland dentist, ... With the LANAP® protocol, which is a laser gum ...
Breaking Medicine News(10 mins):Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 2Health News:Baby Bellies & Beyond Attempts To Break Guinness World Records For “Mommy Moments” Largest Gathering Of Pregnant Women April 19 Outside Florida Hotel & Conference Center 3Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3
... researchers may have found a clue to the blues ... be triggered by the same mechanisms that enable the ... in the December issue of Neuropsychopharmacology, Chong-Bin ... Ph.D., and colleagues activated the immune system in mice ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... facilities in the state of Illinois don,t make it to ... state. But the most severely injured patients did ... are appropriately triaging patients, according to a study in the ...
... MONDAY, Dec. 20 (HealthDay News) -- Continuing a 12-year climb, ... almost one-third of the births in the United States, ... up since 1996 across the board for all age groups ... study and an analyst with the National Center for Health ...
... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) ... receptor antagonists, may raise the risk of pneumonia, new research ... studies on heartburn drugs published between 1985 and 2009. ... drugs is associated with an increased risk of pneumonia," said ...
... prone to develop genital cancer, especially as they grow older. ... both sexes suffer from the condition, which is extremely difficult ... Because of the similarity of the disease to human genital ... responsible. Several human genital cancers, including cervical tumours, are ...
... are more effective than anti-inflammatory drugs and cortisone injections ... This is the conclusion of a thesis presented at ... among other topics, the selection of treatment by healthcare ... and the results from a training programme for tennis ...
Cached Medicine News:Health News:Link between depression and inflammatory response found in mice 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 3Health News:C-Sections Continue 12-Year Climb: U.S. Report 2Health News:C-Sections Continue 12-Year Climb: U.S. Report 3Health News:Heartburn Drugs May Raise Pneumonia Risk 2Health News:Heartburn Drugs May Raise Pneumonia Risk 3Health News:A possible cause -- and cure -- for genital cancer in horses? 2Health News:Training the best treatment for tennis elbow 2
... The Luna is based on a ... At ovulation, a woman's most fertile time, ... egg to be released. At the same ... salt in your saliva. It is these ...
... The FSH Menopause Predictor Test is ... the detection of Follicle Stimulating Hormone ... of body hormone changes related to ... of menopause. The FHS Menopause ...
Inquire...
Pronto Dry is intended for use for the detection of urease enzyme in gastric mucosal biopsy specimens....
Medicine Products: